Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Frontiers in Immunology|July 25, 2022
γ9δ2 T-Cell Expansion and Phenotypic Profile Are Reflected in the CDR3δ Repertoire of Healthy AdultsAnna Vyborova, Anke Janssen, Lucrezia Gatti, et al.
Oncoimmunology|June 7, 2018
Cellular immunotherapy on primary multiple myeloma expanded in a 3D bone marrow niche modelMaaike V J Braham, Monique C Minnema, Tineke Aarts, et al.
Frontiers in Immunology|November 11, 2021
Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor ControlInez Johanna, Patricia Hernández-López, Sabine Heijhuurs, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|November 4, 2014
Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitmentTrudy Straetemans, Cor Berrevoets, Miriam Coccoris, et al.
Blood|September 29, 2012
γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRsCordula Gründer, Suzanne van Dorp, Samantha Hol, et al.
Frontiers in Immunology|March 4, 2026
Pre-existing activation states shape functional heterogeneity of human Vγ9Vδ2 T cellsAnna Vyborova, Laia Gasull-Celades, Peter Brazda, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 29, 2019
TEG001 Insert Integrity from Vector Producer Cells until Medicinal ProductTrudy Straetemans, Anke Janssen, Koen Jansen, et al.
Clinical & Developmental Immunology|March 9, 2012
TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targetsTrudy Straetemans, Mandy van Brakel, Sabine van Steenbergen, et al.
Journal of Leukocyte Biology|February 6, 2020
TEG011 persistence averts extramedullary tumor growth without exerting off-target toxicity against healthy tissues in a humanized HLA-A*24:02 transgenic miceInez Johanna, Patricia Hernández-López, Sabine Heijhuurs, et al.
Pageof 3